231 related articles for article (PubMed ID: 31260789)
1. Optimal two-stage designs for exploratory basket trials.
Zhou H; Liu F; Wu C; Rubin EH; Giranda VL; Chen C
Contemp Clin Trials; 2019 Oct; 85():105807. PubMed ID: 31260789
[TBL] [Abstract][Full Text] [Related]
2. Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.
Kaizer A; Zabor E; Nie L; Hobbs B
PLoS One; 2022; 17(8):e0272367. PubMed ID: 35917296
[TBL] [Abstract][Full Text] [Related]
3. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
4. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
5. Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.
Palmer AC; Plana D; Sorger PK
Cell Syst; 2020 Nov; 11(5):449-460.e2. PubMed ID: 33220857
[TBL] [Abstract][Full Text] [Related]
6. An optimal two-stage exploratory basket trial design with aggregated futility analysis.
Jing N; Liu F; Wu CI; Zhou H; Chen C
Contemp Clin Trials; 2022 May; 116():106741. PubMed ID: 35358718
[TBL] [Abstract][Full Text] [Related]
7. Bayesian basket trial design with false-discovery rate control.
Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols.
Park JJH; Siden E; Zoratti MJ; Dron L; Harari O; Singer J; Lester RT; Thorlund K; Mills EJ
Trials; 2019 Sep; 20(1):572. PubMed ID: 31533793
[TBL] [Abstract][Full Text] [Related]
9. Optimal, minimax and admissible two-stage design for phase II oncology clinical trials.
Qin F; Wu J; Chen F; Wei Y; Zhao Y; Jiang Z; Bai J; Yu H
BMC Med Res Methodol; 2020 May; 20(1):126. PubMed ID: 32434577
[TBL] [Abstract][Full Text] [Related]
10. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
11. Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials.
Wu C; Liu F; Zhou H; Wu X; Chen C
Clin Trials; 2021 Dec; 18(6):673-680. PubMed ID: 34693772
[TBL] [Abstract][Full Text] [Related]
12. Admissible two-stage designs for phase II cancer clinical trials.
Jung SH; Lee T; Kim K; George SL
Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
[TBL] [Abstract][Full Text] [Related]
13. Bayesian basket trial design with exchangeability monitoring.
Hobbs BP; Landin R
Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
[TBL] [Abstract][Full Text] [Related]
14. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors.
Wang X; Wei W
Contemp Clin Trials; 2024 May; 140():107505. PubMed ID: 38521384
[TBL] [Abstract][Full Text] [Related]
15. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
Yoo W; Kim S; Garcia M; Mehta S; Sanai N
BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
[TBL] [Abstract][Full Text] [Related]
17. Boundary problem in Simon's two-stage clinical trial designs.
Shan G; Chen JJ; Ma C
J Biopharm Stat; 2017; 27(1):25-33. PubMed ID: 26881325
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
19. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints.
Kunz CU; Kieser M
Methods Inf Med; 2011; 50(4):372-7. PubMed ID: 21057719
[TBL] [Abstract][Full Text] [Related]
20. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
